Dopamine D2 activity of R-(-)-apomorphine and selected analogs: A microdialysis study

European Journal of Pharmacology

Volumn 387, Issue 1, 2000, Pages 39-45

  Rodenhuis, Nienke ^a   Dijkstra, Durk ^a   Boer, Peter de ^a   Vermeulen, Erik S ^a   Timmerman, Wia ^a   Wikström, Håkan V ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apomorphine; Bioavailability; Dopamine; Microdialysis; N propyl analog; Striatum

Indexed keywords

11 HYDROXY N PROPYLNORAPORPHINE; APOMORPHINE; APORPHINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PROPYLNORAPOMORPHINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG BIOAVAILABILITY; DRUG POTENCY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; APOMORPHINE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SUBCUTANEOUS; MALE; MICRODIALYSIS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2;

EID: 0033984334     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00685-8     Document Type: Article

References (33)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. TINS. 12:1989;366-375.
2. 3H]apomorphine to an aporphine binding site as well as to dopamine sites in tissue from bovine caudate nucleus. Neuropharmacology. 23:1984;885-892.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20:1973;415-455.
4. Campbell A., Kula N.S., Jeppson B., Baldessarini R.J. Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis. Eur. J. Pharmacol. 67:1980;139-142.
5. Campbell A., Baldessarini R.J., Gao Y., Zong R., Neumeyer J.L. R(-) and S(+) stereoisomers of 11-hydroxy- and 11-methoxy-N-n-propylnoraporphine: central dopaminergic behavioral activity in the rat. Neuropharmacology. 29:1990;527-536.
6. Cannon J.G., Qijie P. Isomeric monomethyl ether derivatives of (RS)-9,10-dihydroxyaporphine ("isoapomorphine") as possible products of metabolism by catechol-O-methyltransferase. J. Med. Chem. 34:1991;1079-1082.
7. Colosimo C., Merello M., Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin. Neuropharmacol. 17:1994;243-259.
8. Colpaert F.C., Van Bever W.F., Leysen J.E. Apomorphine; chemistry, pharmacology, biochemistry. Int. Rev. Neurobiol. 19:1976;225.
9. Costall B., Naylor R.J., Neumeyer J.L. Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur. J. Pharmacol. 31:1975;1-16.
10. Cotzias G., Papavasiliou P.S., Tolosa E.S., Mendez J.S., Bell-Midura M. Treatment of Parkinson's disease with aporphines. N. Engl. J. Med. 294:1976;567.
11. Duvoisin R. History of Parkinsonism. Pharmacol. Ther. 32:1987;1-17.
12. Frankel J.P., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J. Neurol., Neurosurg. Psychiatry. 53:1990;96-101.
13. Gao Y.G., Ram V.J., Campbell A., Kula N.S., Baldessarini R.J., Neumeyer J.L. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain. J. Med. Chem. 33:1990;39-44.
14. Gassen M., Glinka Y., Pinchasi B., Youdim M.B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308:1996;219-225.
15. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:1966;925-962.
16. Hughes A.J., Bishop S., Kleedorfer B., Turjanski N., Fernandez W., Lees A.J., Stern G.M. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Movement Disorders. 8:1993;165-170.
17. Kelly P.H., Miller R.J., Neumeyer J.L. Aporphines: 16. Action of aporphine alkaloids on locomotor activity in rats with 6-hydroxydopamine lesions of the nucleus accumbens. Eur. J. Pharmacol. 35:1976;85-92.
18. Marsden C.D., Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. I:1976;292-296.
19. Marsden C.D., Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. I:1977;345-349.
20. Neumeyer J.L., Baldessarini R.J. Apomorphine: new uses for an old drug. Pharm. News. 4:1997;12-16.
21. Neumeyer J.L., Gao Y.G., Kula N.S., Baldessarini R.J. R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue. J. Med. Chem. 34:1991;24-28.
22. Nishibayashi S., Asanuma M., Kohno M., Gomez Vargas M., Ogawa N. Scavenging effects of dopamine agonists on nitric oxide radicals. J. Neurochem. 67:1996;2208-2211.
23. Ogawa N., Tanaka K., Asanuma M., Kawai M., Masumizu T., Kohno M., Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657:1994;207-213.
24. Olanow C.W., Jenner P., Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44:1998;S167-S174.
25. Papavasiliou P.S., Cotzias G., Rosal V.L.F., Miller S.T. Treatment of Parkinsonism with N-n-propyl norapomorphine and levodopa (with of without carbidopa). Arch. Neurol. 35:1978;787-791.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1982;Academic Press, New York.
27. Piercey M.F., Camacho-Ochoa M., Smith M.W. Functional roles for dopamine-receptor subtypes. Clin. Neuropharmacol. 18(Suppl. 1):1995;S34-S42.
28. 1 receptors. J. Med. Chem. 33:1990;600-607.
29. Schoenfeld R.I., Neumeyer J.L., Dafeldecker W., Roffler Tarlov S. Comparison of structural and stereoisomers of apomorphine on stereotyped behavior of the rat. Eur. J. Pharmacol. 30:1975;63-68.
30. Stibe C.M.H., Kempster P.A., Lees A.J., Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988;403-406.
31. Westerink B.H.C. Monitoring molecules in the conscious brain by microdialysis. Trends Anal. Chem. 11:1992;176-182.
32. Westerink B.H., de Boer P., Timmerman W., De Vries J.B. In vivo evidence for the existence of autoreceptors on dopaminergic, serotonergic, and cholinergic neurons in the brain. Ann. N. Y. Acad. Sci. 604:1990;492-504.
33. Yoshikawa T., Minamiyama Y., Naito Y., Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J. Neurochem. 62:1994;1034-1038.